[go: up one dir, main page]

DK1100542T3 - PEG-uratoxidasekonjugater og anvendelsen heraf - Google Patents

PEG-uratoxidasekonjugater og anvendelsen heraf

Info

Publication number
DK1100542T3
DK1100542T3 DK99937745T DK99937745T DK1100542T3 DK 1100542 T3 DK1100542 T3 DK 1100542T3 DK 99937745 T DK99937745 T DK 99937745T DK 99937745 T DK99937745 T DK 99937745T DK 1100542 T3 DK1100542 T3 DK 1100542T3
Authority
DK
Denmark
Prior art keywords
peg
uricase
urate oxidase
kda
poly
Prior art date
Application number
DK99937745T
Other languages
English (en)
Inventor
L David Williams
Mark G P Saifer
Merry R Sherman
Michael S Hershfield
Susan J Kelly
Original Assignee
Mountain View Pharmaceuticals
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals, Univ Duke filed Critical Mountain View Pharmaceuticals
Priority claimed from PCT/US1999/017514 external-priority patent/WO2000007629A2/en
Application granted granted Critical
Publication of DK1100542T3 publication Critical patent/DK1100542T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK99937745T 1998-08-06 1999-08-02 PEG-uratoxidasekonjugater og anvendelsen heraf DK1100542T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21931898P 1998-08-06 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (1)

Publication Number Publication Date
DK1100542T3 true DK1100542T3 (da) 2005-10-17

Family

ID=22818799

Family Applications (4)

Application Number Title Priority Date Filing Date
DK05011069.1T DK1588716T3 (da) 1998-08-06 1999-08-02 Peg-uratoxidase-konjugater og anvendelse deraf
DK09175303.8T DK2158923T3 (da) 1998-08-06 1999-08-02 Peg-uratoxidase-konjugater og anvendelse deraf
DK10180672.7T DK2316475T3 (da) 1998-08-06 1999-08-02 Isoleret tetramer urikase
DK99937745T DK1100542T3 (da) 1998-08-06 1999-08-02 PEG-uratoxidasekonjugater og anvendelsen heraf

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK05011069.1T DK1588716T3 (da) 1998-08-06 1999-08-02 Peg-uratoxidase-konjugater og anvendelse deraf
DK09175303.8T DK2158923T3 (da) 1998-08-06 1999-08-02 Peg-uratoxidase-konjugater og anvendelse deraf
DK10180672.7T DK2316475T3 (da) 1998-08-06 1999-08-02 Isoleret tetramer urikase

Country Status (11)

Country Link
US (11) US6576235B1 (da)
EP (3) EP1588716B1 (da)
CN (3) CN1264575C (da)
AT (2) ATE498409T1 (da)
CA (2) CA2728907C (da)
CY (2) CY1112287T1 (da)
DE (2) DE69943205D1 (da)
DK (4) DK1588716T3 (da)
ES (4) ES2649840T3 (da)
PT (4) PT2158923E (da)
ZA (1) ZA200101814B (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
PT2158923E (pt) 1998-08-06 2013-06-04 Univ Duke Conjugados de peg-urato oxidase e sua utilização
ES2352451T3 (es) 1998-08-06 2011-02-18 Duke University Urato oxidasa.
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
DK2298278T3 (da) 2002-06-07 2016-02-01 Dyax Corp Forebyggelse og reduktion af blodtab og inflammatorisk respons
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
CN102319437B (zh) * 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
AU2004238364A1 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
BRPI0411160A (pt) * 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
CA2525497A1 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
PT1663281E (pt) * 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
RU2298560C2 (ru) * 2004-04-30 2007-05-10 Открытое Акционерное Общество "Верофарм" Конъюгаты белка и производного полиэтиленгликоля, фармацевтическая композиция, способ борьбы с вирусной инфекцией
AU2005245910A1 (en) * 2004-05-21 2005-12-01 Xencor, Inc C1q family member proteins with altered immunogenicity
US20080317728A1 (en) * 2004-06-21 2008-12-25 University Of Florida Research Foundation, Inc. Lowering Uric Acid to Prevent or Accelerate Recovery of Acute Renal Failure
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
US9534013B2 (en) * 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
AU2006235437B2 (en) * 2005-04-11 2011-11-24 Horizon Therapeutics Usa, Inc. A variant form of urate oxidase and use thereof
EP1883425A1 (en) * 2005-05-23 2008-02-06 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CN101302501B (zh) * 2007-05-10 2012-07-04 刘国安 聚乙二醇化尿酸氧化酶化合物及其制备方法和其制剂及应用
AU2008289005A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009045553A1 (en) * 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
EP2271750A4 (en) * 2008-03-24 2011-07-27 Althea Technologies Inc URICASE COMPOSITIONS AND METHODS OF USE
EP2165705A1 (en) 2008-09-18 2010-03-24 Centre National de la Recherche Scientifique (CNRS) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN101875922B (zh) * 2009-04-30 2012-02-22 重庆医科大学 一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用
EP2446260B1 (en) 2009-06-25 2018-12-26 Horizon Pharma Rheumatology LLC Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102051348B (zh) * 2009-10-27 2012-10-03 重庆富进生物医药有限公司 人源化重组尿酸酶及其突变体
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
CN101928704A (zh) * 2010-03-04 2010-12-29 杭州北斗生物技术有限公司 黄曲霉尿酸氧化酶的聚乙二醇修饰物及其制备方法
WO2011127393A2 (en) * 2010-04-08 2011-10-13 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN102757945B (zh) * 2011-04-28 2015-03-18 杭州俊丰生物工程有限公司 人尿酸氧化酶蛋白及其制备方法和其聚乙二醇结合物
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102260653B (zh) * 2011-06-30 2013-04-03 荣俊 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
US10198063B1 (en) * 2014-11-06 2019-02-05 Avago Technologies International Sales Pte. Limited Average power saving modes and power architecture for read channel product
HK1252542A1 (zh) * 2015-05-15 2019-05-31 Medimmune, Llc 改进的尿酸酶序列和治疗方法
SG10202111439SA (en) 2015-10-15 2021-11-29 Les Laboratoires Servier Sas Combination therapy for treating malignancies
EA039829B1 (ru) 2015-10-15 2022-03-17 Аджиос Фармасьютикалз, Инк. Комбинированная терапия для лечения злокачественных опухолей
KR102857973B1 (ko) 2015-12-11 2025-09-10 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
CN108103079B (zh) * 2017-06-20 2021-07-13 北京锦篮基因科技有限公司 一种高尿酸血症的基因治疗药物
AU2018297309A1 (en) 2017-07-07 2020-01-30 Allena Pharmaceuticals, Inc. Recombinant uricase enzyme
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020228618A1 (zh) 2019-05-10 2020-11-19 重庆派金生物科技有限公司 聚乙二醇修饰的尿酸氧化酶
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
CN113144174B (zh) * 2020-01-22 2023-07-04 杭州远大生物制药有限公司 治疗高尿酸相关性疾病的药物
EP4192581A4 (en) 2020-08-10 2024-09-25 Horizon Therapeutics USA, Inc. METHODS OF TREATING GOUT
WO2022097141A1 (en) * 2020-11-03 2022-05-12 Protalix Ltd. Modified uricase and uses thereof
KR20220077590A (ko) 2020-12-02 2022-06-09 주식회사 프로앱텍 Candida Utilis 유래 요산산화효소-알부민 복합체 및 이의 제조 방법
CN115197922B (zh) * 2021-04-09 2024-05-14 派格生物医药(苏州)股份有限公司 尿酸酶或其同功异型物及其制备方法
CN114262405B (zh) * 2021-12-24 2023-02-07 浙江震东新材料有限公司 一种短链含氟防水防油剂共聚物及其制备方法
CN114813998B (zh) * 2022-03-24 2023-05-23 天津键凯科技有限公司 一种聚合物的检测方法
WO2025015090A1 (en) 2023-07-11 2025-01-16 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding uricase and methods of using the same
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
CN120137926B (zh) * 2025-05-14 2025-09-05 杭州师范大学 一种嗜热毁丝霉尿酸酶突变体及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (da)
US3451996A (en) 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US3931399A (en) 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4169764A (en) 1975-08-13 1979-10-02 Ajinomoto Co., Inc. Process for production of urokinase
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4064010A (en) 1976-07-21 1977-12-20 Eastman Kodak Company Purification of uricase
US4301153A (en) 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
US4425431A (en) 1978-04-20 1984-01-10 Toyo Soda Manufacturing Co., Ltd. Production of an allose-containing polysaccharide
US4312979A (en) 1978-04-20 1982-01-26 Toyo Soda Manufacturing Co., Ltd. Polysaccharides containing allose
JPS6031472B2 (ja) 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
US4251431A (en) 1979-01-16 1981-02-17 Shell Oil Company Lubricating greases
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
FR2475900A1 (fr) 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
CH651308A5 (de) 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
JPS5740503A (en) 1980-08-22 1982-03-06 Seikagaku Kogyo Co Ltd Separation of saccharides
FR2497006A1 (fr) 1980-12-24 1982-06-25 Ind Electro Ste Gle Contacts electriques pour cables coaxiaux et cables bifilaires
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4485176A (en) 1982-06-28 1984-11-27 E. I. Du Pont De Nemours & Company Turbidimetric method for measuring protein in urine and cerebrospinal fluid
EP0109688A3 (en) 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0671425B2 (ja) 1985-06-05 1994-09-14 サッポロビール株式会社 ウリカ−ゼおよびその製造法
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
AU597924B2 (en) 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
AU612133B2 (en) 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
AU609824B2 (en) 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH01216939A (ja) 1988-02-24 1989-08-30 Hoechst Japan Kk 末熟児頭蓋内出血阻止剤
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5955336A (en) 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
JP3148208B2 (ja) 1988-10-31 2001-03-19 富士ゼロックス株式会社 マルチ出力トレイ付プリントサーバおよびプリントシステム
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
DE69032406T2 (de) 1989-08-23 1998-10-29 Zvi Fuks Wundheilmittel enthaltend heparanase
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
YU66892A (sh) 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
JP3875730B2 (ja) 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 自己免疫疾患の予防治療剤
US6385312B1 (en) 1993-02-22 2002-05-07 Murex Securities, Ltd. Automatic routing and information system for telephonic services
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5783421A (en) 1993-04-09 1998-07-21 Bio-Technology General Corp. DNA encoding novel polypeptide having Factor Xa inhibitory activity
JPH08511157A (ja) 1993-04-09 1996-11-26 バイオ − テクノロジー・ジェネラル・コーポレーション Ｘａファクター阻害活性を有する新規ポリペプチド
WO1994023740A1 (en) 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1995011987A1 (en) 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
KR960705579A (ko) * 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5795776A (en) 1994-03-22 1998-08-18 Bio-Technology General Corp. Expression plasmids regulated by an OSMB promoter
FI96317C (fi) 1994-05-31 1996-06-10 Exavena Oy Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5633227A (en) 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CN1168694A (zh) 1994-12-07 1997-12-24 诺沃挪第克公司 具有减弱的变应原性的多肽
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116696A (en) 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
ATE342729T1 (de) 1997-01-15 2006-11-15 Phoenix Pharmacologics Inc Modifizierter tumor-nekrosefaktor
KR100369838B1 (ko) 1997-02-26 2003-09-29 주식회사 엘지생명과학 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법
US6821763B2 (en) 1997-07-04 2004-11-23 Ajinomoto Co., Inc. Process for producing microbial transglutaminase
JPH1175876A (ja) 1997-07-04 1999-03-23 Ajinomoto Co Inc 新規な微生物トランスグルタミナーゼの製造法
ATE274522T1 (de) * 1998-06-01 2004-09-15 Genentech Inc Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie
KR100488848B1 (ko) 1998-08-06 2005-05-11 듀크 유니버서티 피이지-유레이트 옥시데이즈 접합체 및 그의 이용
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ES2352451T3 (es) 1998-08-06 2011-02-18 Duke University Urato oxidasa.
PT2158923E (pt) 1998-08-06 2013-06-04 Univ Duke Conjugados de peg-urato oxidase e sua utilização
US20060188971A1 (en) 1998-08-06 2006-08-24 Duke University Urate oxidase
US6425448B1 (en) * 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
JP5219322B2 (ja) 2000-02-14 2013-06-26 クリニカル ディシジョン サポート，エルエルシー 自動診断システムおよび方法
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
AU2002365360A1 (en) 2001-11-28 2003-06-10 Biopolymed Inc. Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
ATE364092T1 (de) 2003-01-09 2007-06-15 Genentech Inc Reinigung von polypeptiden
JP4273998B2 (ja) 2004-02-26 2009-06-03 学校法人東海大学 プロテオーム解析用試料の調製方法
CN103088038B (zh) 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
AU2006235437B2 (en) 2005-04-11 2011-11-24 Horizon Therapeutics Usa, Inc. A variant form of urate oxidase and use thereof
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP2100122A4 (en) 2006-11-21 2010-01-06 Univ Southern California TESTS FOR THE DETECTION OF POLY (ETHYLENE GLYCOL) ANTIBODIES AND KITS FOR IMPLEMENTATION
EP2446260B1 (en) 2009-06-25 2018-12-26 Horizon Pharma Rheumatology LLC Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
JP5746101B2 (ja) 2012-06-18 2015-07-08 コスメディ製薬株式会社 マイクロニードルの迅速溶解法

Also Published As

Publication number Publication date
CY1112287T1 (el) 2015-12-09
HK1103303A1 (en) 2007-12-14
US20160160188A1 (en) 2016-06-09
CA2728907A1 (en) 2000-02-17
HK1141738A1 (en) 2010-11-19
ATE498409T1 (de) 2011-03-15
CN102161984A (zh) 2011-08-24
US20080031864A1 (en) 2008-02-07
CN1896231A (zh) 2007-01-17
ES2404074T3 (es) 2013-05-23
CN1322141A (zh) 2001-11-14
PT2316475T (pt) 2017-12-21
ZA200101814B (en) 2002-05-27
US20030166249A1 (en) 2003-09-04
DE69925917T2 (de) 2006-05-11
US7723089B2 (en) 2010-05-25
ES2361190T3 (es) 2011-06-14
PT1100542E (pt) 2005-11-30
US8067553B2 (en) 2011-11-29
DK2158923T3 (da) 2013-03-25
CY1119848T1 (el) 2018-06-27
EP2158923A1 (en) 2010-03-03
CN1264575C (zh) 2006-07-19
EP1588716A1 (en) 2005-10-26
PT1588716E (pt) 2011-05-25
PT2158923E (pt) 2013-06-04
EP2316475A1 (en) 2011-05-04
ES2649840T3 (es) 2018-01-15
DK1588716T3 (da) 2011-05-23
EP2316475B1 (en) 2017-10-04
US20140363414A1 (en) 2014-12-11
CN102161984B (zh) 2016-06-01
DK2316475T3 (da) 2017-11-20
EP1588716B1 (en) 2011-02-16
ES2245114T3 (es) 2005-12-16
CA2728907C (en) 2015-11-24
US9885024B2 (en) 2018-02-06
US20100323423A1 (en) 2010-12-23
US7927589B2 (en) 2011-04-19
HK1037330A1 (en) 2002-02-08
CA2338665C (en) 2011-01-18
DE69943205D1 (de) 2011-03-31
DE69925917D1 (de) 2005-07-28
US8618267B2 (en) 2013-12-31
US20180223263A1 (en) 2018-08-09
CA2338665A1 (en) 2000-02-17
CN1896231B (zh) 2012-09-05
US20100323422A1 (en) 2010-12-23
US20130052677A1 (en) 2013-02-28
ATE298251T1 (de) 2005-07-15
EP2158923B1 (en) 2013-02-27
US20120149083A1 (en) 2012-06-14
US6576235B1 (en) 2003-06-10
US20050014240A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
CY1119848T1 (el) Απομονωμενη τετραμερικη ουρικαση
NZ509595A (en) Peg-urate oxidase conjugates and use thereof
AU2001296962A1 (en) Pegylated interleukin-10
AU7761594A (en) Polyethylene glycols
HK1054684A1 (zh) 包含高分子量聚环氧乙烷的多价平台分子
DE60141742D1 (de) Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
CA2304976A1 (en) Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels
WO2003055526A3 (en) Erythropoietin conjugates
JP2003521937A5 (da)
UA86744C2 (en) Pegylated factor vii glycoforms
ATE385422T1 (de) Bisacyloxypropylcystein-konjugate und deren verwendung
CY1114005T1 (el) Συζευγματα peg-ουρικης οξειδασης και χρηση αυτων
EP1025860A3 (de) Proteinhaltige Hydrogele